Innovent Biologics's total assets for Q4 2025 were ¥37.36B, an increase of 58.36% from the previous quarter. HK:1801 total liabilities were ¥17.20B for the fiscal quarter, a 87.53% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.